CohBar, Inc.

Equities

CWBR

US19249J3077

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 01:02:28 2024-05-15 pm EDT			5-day change	1st Jan Change
0.7601 ^USD	-23.98%		-5.11%	+2.72%

Jan. 23	North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up	DJ
Jan. 16	North American Morning Briefing : Stock Futures -2-	DJ

Cohbar, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 10, 2021 at 04:11 pm EDT

CohBar, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 5.202 million compared to USD 2.935 million a year ago. Net loss was USD 5.223 million compared to USD 4.102 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.09 a year ago. For the half year, operating loss was USD 9.215 million compared to USD 6.217 million a year ago. Net loss was USD 9.261 million compared to USD 8.320 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.19 a year ago.

Latest news about CohBar, Inc.

North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up	Jan. 23	DJ
North American Morning Briefing : Stock Futures -2-	Jan. 16	DJ
North American Morning Briefing : Samsung Warning Knocks Tech Stocks	Jan. 09	DJ
North American Morning Briefing : Stock Futures Struggle After Weak China Data	Jan. 02	DJ
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
North American Morning Briefing : Traders Eye -2-	Dec. 12	DJ
North American Morning Briefing : China Outlook -2-	Dec. 05	DJ
CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index	Dec. 01	CI
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	Nov. 28	DJ
CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index	Nov. 28	CI
North American Morning Briefing : All Eyes on -2-	Nov. 21	DJ
CohBar, Inc. Announces Resignation of Jeffery F. Biunno as Chief Financial Officer	Nov. 13	CI
CohBar, Inc. Announces Resignation of Joseph J. Sarret as Chief Executive Officer	Nov. 13	CI
CohBar, Inc. Announces Executive Changes	Nov. 13	CI
Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. in a reverse merger transaction.	Oct. 31	CI
North American Morning Briefing : Focus Shifts to -2-	23-08-21	DJ
CohBar, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma	23-06-05	CI
Wall Street Set to Open Lower as Investors Await Progress on Debt-Ceiling Talks Ahead of Fed Minutes Release	23-05-24	MT
US Futures Lower as Investors Eye Debt Ceiling Talks, Await Fed Minutes Release	23-05-24	MT
Top Premarket Decliners	23-05-24	MT
Top Midday Gainers	23-05-23	MT
Transcript : CohBar, Inc., Morphogenesis, Inc. - M&A Call	23-05-23
Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. for approximately $130 million in a reverse merger transaction.	23-05-22	CI
Morphogenesis, Inc. announced that it expects to receive $15 million in funding from CohBar, Inc.	23-05-22	CI

Chart CohBar, Inc.

Duration

Period

More charts

Company Profile

CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
COHBAR, INC.	+2.72%	2.91M
MODERNA, INC.	+29.37%	49.18B
IQVIA HOLDINGS INC.	+1.02%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.65%	18.71B
BIO-TECHNE CORPORATION	+8.10%	13.26B
MEDPACE HOLDINGS, INC.	+32.23%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.91%	11.99B

Other Biotechnology & Medical Research

CohBar, Inc.

Equities

CWBR

US19249J3077

Biotechnology & Medical Research

Cohbar, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

Latest news about CohBar, Inc.

Chart CohBar, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research